Advertisement

Related Videos

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Peter Clark, MA, MD, FRCP: A Payer Perspective

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Advertisement

Advertisement




Aug
03
Today In Oncology
FDA Approves Radionuclide Therapy Plus ARPI for mAPMN/S Prostate Cancer
Quantum Machine Learning Framework Improves Prediction of Antigen Presentation and Immunotherapy Response
Researchers Identify Donor NK Cell Subset That Impairs CAR NK Cell Therapy and Demonstrate a Manufacturing Solution
Enfortumab Vedotin Plus Pembrolizumab Improves Outcomes in Cisplatin-Eligible Muscle-Invasive Bladder Cancer
Safety and Efficacy of IL-10–Expressing CAR T-Cell Therapy in Relapsed or Refractory DLBCL
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo